Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aston Sci. Inc.
Not provided
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a residual invasive cancer in the breast(non-pCR) after neoadjuvant treatment
Has stage I, II, or III disease prior to surgery per American Joint Committee on Cancer (AJCC)
HER 2 1+ by IHC or HER2 2+by IHC without gene amplification by ISH, as defined by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines.
Hormone receptor (ER and PR) negative by ASCO/CAP guidelines
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Demonstrates adequate organ function.
You may not be if
Has a history of hypersensitivity or other contraindications to rhGM-CSF
Has a history of invasive malignancy ≤5 years prior to first administration of investigational drug except for adequately treated non-melanoma skin cancer or carcinoma in situ.
Is on immune suppression therapy or has a history of immune suppression therapy ≤4 weeks prior to the first administration of investigational drugs
Has a history of autoimmune disease or inflammatory disease
Has active infection including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Is pregnant or breastfeeding or expecting to conceive children
